C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates ...

Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...

People with hepatitis C virus who inject drugs could be evaluated for cure approximately 2 months earlier than current ...

Detailed price information for Atea Pharmaceuticals Inc (AVIR-Q) from The Globe and Mail including charting and trades.